Antibe Therapeutics (ATE) Stock Price, News & Analysis

Company Overview

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 167,044 shs
• Average Volume: 135,475 shs
• Market Capitalization: C$15.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: TSE:ATE
• CIK: N/A
• Web: www.antibethera.com
• Phone: +1-905-5705103
• Fax: N/A
• Employees: 11
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): C($0.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -C$18.24 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -52.72%
• Return on Assets: -19.13%

Debt

• Debt-to-Equity Ratio: 0.29
• Current Ratio: 10.06
• Quick Ratio: 9.58

Sales & Book Value

• Annual Sales: C$9.71 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 0.61
• Book Value: C$0.49 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 53,010,000
• Free Float: N/A
• Market Cap: C$15.64 million
• Optionable: Not Optionable
• Beta: 0.19